Literature DB >> 29184184

The devotion to surrogate outcomes in drug development for liver disease.

Ian A Rowe1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29184184     DOI： 10.1038/nrgastro.2017.155

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  The idolatry of the surrogate.

Authors:  John S Yudkin; Kasia J Lipska; Victor M Montori
Journal:  BMJ       Date:  2011-12-28

2.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  J Hepatol       Date:  2017-08-10       Impact factor: 25.083

3.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

Review 4.  Direct-acting antivirals for chronic hepatitis C.

Authors:  Janus C Jakobsen; Emil Eik Nielsen; Joshua Feinberg; Kiran Kumar Katakam; Kristina Fobian; Goran Hauser; Goran Poropat; Snezana Djurisic; Karl Heinz Weiss; Milica Bjelakovic; Goran Bjelakovic; Sarah Louise Klingenberg; Jian Ping Liu; Dimitrinka Nikolova; Ronald L Koretz; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-06-06

5.  Endpoints and clinical trial design for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Elizabeth M Brunt; David E Kleiner; Kris V Kowdley; Naga Chalasani; Joel E Lavine; Vlad Ratziu; Arthur McCullough
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

6.  Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness.

Authors:  Hamish A Innes; Sharon J Hutchinson; Stephen Barclay; Elaine Cadzow; John F Dillon; Andrew Fraser; David J Goldberg; Peter R Mills; Scott A McDonald; Judith Morris; Adrian Stanley; Peter Hayes
Journal:  Hepatology       Date:  2013-01-08       Impact factor: 17.425

Review 7.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

8.  Systematic review: Current evidence in non-alcoholic fatty liver disease lacks relevance to patients with advanced fibrosis.

Authors:  Richard Parker; James Hodson; Ian A C Rowe
Journal:  J Gastroenterol Hepatol       Date:  2017-05       Impact factor: 4.029

9.  A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.

Authors:  Scott L Friedman; Vlad Ratziu; Stephen A Harrison; Manal F Abdelmalek; Guruprasad P Aithal; Juan Caballeria; Sven Francque; Geoffrey Farrell; Kris V Kowdley; Antonio Craxi; Krzysztof Simon; Laurent Fischer; Liza Melchor-Khan; Jeffrey Vest; Brian L Wiens; Pamela Vig; Star Seyedkazemi; Zachary Goodman; Vincent Wai-Sun Wong; Rohit Loomba; Frank Tacke; Arun Sanyal; Eric Lefebvre
Journal:  Hepatology       Date:  2018-01-29       Impact factor: 17.425

10.  The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.

Authors:  Rohit Loomba; Eric Lawitz; Parvez S Mantry; Saumya Jayakumar; Stephen H Caldwell; Hays Arnold; Anna Mae Diehl; C Stephen Djedjos; Ling Han; Robert P Myers; G Mani Subramanian; John G McHutchison; Zachary D Goodman; Nezam H Afdhal; Michael R Charlton
Journal:  Hepatology       Date:  2017-12-26       Impact factor: 17.425
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.